QuidelOrtho Corp
QDEL28.580USD
-0.380-1.31%
Close 04/29, 16:00（ET）Quotes delayed by 15 min
1.92BMarket Cap
LossP/E TTM
More Details of QuidelOrtho Corp Company
QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
Company Info
Company codeQDEL
Company nameQuidelOrtho Corp
IPO dateFeb 01, 1991
Founded at2021
CEOMr. Brian J. Blaser
Number of employees6600
Security typeOrdinary Share
Fiscal year-endFeb 01
Address9975 Summers Ridge Road
CitySAN DIEGO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code92121
Phone18585521100
Websitehttps://www.quidelortho.com/
Company codeQDEL
IPO dateFeb 01, 1991
Founded at2021
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Kenneth F. Buechler, Ph.D.
Dr. Kenneth F. Buechler, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
89.24K
--
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
67.62K
--
Ms. Michelle A. Hodges, J.D.
Ms. Michelle A. Hodges, J.D.
Senior Vice President, Corporate Secretary, Chief Legal Officer
Senior Vice President, Corporate Secretary, Chief Legal Officer
23.16K
+9.93%
Mr. Joseph M. Busky
Mr. Joseph M. Busky
Chief Financial Officer
Chief Financial Officer
19.17K
+20.97%
Mr. Edward L. (Ed) Michael
Mr. Edward L. (Ed) Michael
Independent Director
Independent Director
15.70K
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
8.13K
--
Ms. Evelyn S. Dilsaver
Ms. Evelyn S. Dilsaver
Independent Director
Independent Director
--
--
Mr. Lee Bowman
Mr. Lee Bowman
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
Mr. Joseph D. Wilkins, Jr.
Mr. Joseph D. Wilkins, Jr.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Kenneth F. Buechler, Ph.D.
Dr. Kenneth F. Buechler, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
89.24K
--
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
67.62K
--
Ms. Michelle A. Hodges, J.D.
Ms. Michelle A. Hodges, J.D.
Senior Vice President, Corporate Secretary, Chief Legal Officer
Senior Vice President, Corporate Secretary, Chief Legal Officer
23.16K
+9.93%
Mr. Joseph M. Busky
Mr. Joseph M. Busky
Chief Financial Officer
Chief Financial Officer
19.17K
+20.97%
Mr. Edward L. (Ed) Michael
Mr. Edward L. (Ed) Michael
Independent Director
Independent Director
15.70K
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
8.13K
--
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Labs
1.43B
51.27%
Point-of-Care
694.10M
24.94%
Immunohematology
522.60M
18.78%
Donor Screening
115.50M
4.15%
Molecular Diagnostic Solutions
24.00M
0.86%
By RegionUSD
Name
Revenue
Proportion
United States
1.57B
56.37%
Foreign
1.21B
43.63%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Labs
1.43B
51.27%
Point-of-Care
694.10M
24.94%
Immunohematology
522.60M
18.78%
Donor Screening
115.50M
4.15%
Molecular Diagnostic Solutions
24.00M
0.86%
Shareholder
Update time: Sun, Feb 23
Update time: Sun, Feb 23
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
T. Rowe Price Investment Management, Inc.
16.66%
BlackRock Institutional Trust Company, N.A.
11.54%
The Vanguard Group, Inc.
10.08%
Rubric Capital Management LP
8.23%
Invesco Advisers, Inc.
4.78%
Other
48.71%
Shareholder Statistics
Shareholder
Proportion
T. Rowe Price Investment Management, Inc.
16.66%
BlackRock Institutional Trust Company, N.A.
11.54%
The Vanguard Group, Inc.
10.08%
Rubric Capital Management LP
8.23%
Invesco Advisers, Inc.
4.78%
Other
48.71%
Type
Shareholder
Proportion
Investment Advisor
46.41%
Investment Advisor/Hedge Fund
38.01%
Hedge Fund
20.96%
Research Firm
1.63%
Sovereign Wealth Fund
1.20%
Pension Fund
1.17%
Individual Investor
0.78%
Bank and Trust
0.59%
Family Office
0.15%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
709
74.95M
111.12%
-12.34M
2024Q4
747
75.07M
111.30%
-13.02M
2024Q3
744
73.58M
109.44%
-4.02M
2024Q2
767
70.18M
104.79%
-7.57M
2024Q1
799
67.05M
100.24%
-5.28M
2023Q4
828
68.21M
102.09%
-2.95M
2023Q3
842
70.19M
105.17%
-4.01M
2023Q2
860
68.99M
103.61%
-6.94M
2023Q1
894
68.68M
103.29%
-6.80M
2022Q4
939
69.19M
108.75%
-5.89M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
T. Rowe Price Investment Management, Inc.
11.24M
16.66%
+1.84M
+19.59%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
7.79M
11.54%
+1.09M
+16.28%
Dec 31, 2024
The Vanguard Group, Inc.
6.80M
10.08%
-21.19K
-0.31%
Dec 31, 2024
Rubric Capital Management LP
5.55M
8.23%
+1.35M
+32.14%
Dec 31, 2024
Invesco Advisers, Inc.
3.23M
4.78%
+1.44M
+81.05%
Dec 31, 2024
State Street Global Advisors (US)
2.27M
3.37%
+366.13K
+19.19%
Dec 31, 2024
ArrowMark Colorado Holdings, LLC
1.98M
2.93%
+100.52K
+5.35%
Dec 31, 2024
D. E. Shaw & Co., L.P.
1.73M
2.56%
+50.77K
+3.03%
Dec 31, 2024
Fidelity Management & Research Company LLC
1.25M
1.85%
+30.51K
+2.50%
Dec 31, 2024
Dimensional Fund Advisors, L.P.
1.22M
1.8%
+107.78K
+9.72%
Dec 31, 2024
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
Invesco S&P SmallCap Health Care ETF
1.57%
SPDR S&P Health Care Equipment ETF
1.45%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.89%
Ballast Small/Mid Cap ETF
0.48%
WisdomTree US SmallCap Quality Growth Fund
0.39%
SPDR S&P 600 Small Cap Value ETF
0.34%
iShares S&P Small-Cap 600 Value ETF
0.33%
VictoryShares US Small Mid Cap Value Momentum ETF
0.28%
Avantis US Small Cap Value ETF
0.27%
JPMorgan Fundamental Data Science Mid Core ETF
0.26%
View more
Invesco S&P SmallCap Health Care ETF
Proportion1.57%
SPDR S&P Health Care Equipment ETF
Proportion1.45%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion0.89%
Ballast Small/Mid Cap ETF
Proportion0.48%
WisdomTree US SmallCap Quality Growth Fund
Proportion0.39%
SPDR S&P 600 Small Cap Value ETF
Proportion0.34%
iShares S&P Small-Cap 600 Value ETF
Proportion0.33%
VictoryShares US Small Mid Cap Value Momentum ETF
Proportion0.28%
Avantis US Small Cap Value ETF
Proportion0.27%
JPMorgan Fundamental Data Science Mid Core ETF
Proportion0.26%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data